For research use only. Not for therapeutic Use.
rel-VU6021625 is the less active relative configuration of VU6021625 (HY-160440A). VU6021625 is a potent and selective mAChR M4 antagonist with IC50 values of 0.44 nM and 57 nM for human M4, rat M4, respectively[1].
| Catalog Number | I040125 |
| CAS Number | 2307718-96-1 |
| Synonyms | (3aR,6aS)-N-[6-(2-methylindazol-5-yl)pyridazin-3-yl]-2-(oxan-4-ylmethyl)-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-5-amine |
| Molecular Formula | C25H32N6O |
| Purity | ≥95% |
| InChI | InChI=1S/C25H32N6O/c1-30-14-21-10-18(2-3-24(21)29-30)23-4-5-25(28-27-23)26-22-11-19-15-31(16-20(19)12-22)13-17-6-8-32-9-7-17/h2-5,10,14,17,19-20,22H,6-9,11-13,15-16H2,1H3,(H,26,28)/t19-,20+,22? |
| InChIKey | YGZMGSNKRRWPDT-RLAPIPATSA-N |
| SMILES | CN1C=C2C=C(C=CC2=N1)C3=NN=C(C=C3)NC4CC5CN(CC5C4)CC6CCOCC6 |
| Reference | [1]. Moehle MS, et al. Discovery of the First Selective M4 Muscarinic Acetylcholine Receptor Antagonists with in Vivo Antiparkinsonian and Antidystonic Efficacy. ACS Pharmacol Transl Sci. 2021 Aug 2;4(4):1306-1321. |
